FierceBiotech 19 mars 2026 Phage-focused BiomX resets after adverse events derail pipeline, considers pivot to defense sector
FierceBiotech 19 mars 2026 Syneos Health scoops up Chinese CRO to secure place in ‘rapidly growing market’
FierceBiotech 19 mars 2026 Lilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trial
FierceBiotech 19 mars 2026 Rare disease advocates stage 'funeral' at FDA, demand 4 actions of agency and Congress
FierceBiotech 18 mars 2026 Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome
FierceBiotech 18 mars 2026 JenaValve's Trilogy valve secures FDA's 1st approval in aortic regurgitation
FierceBiotech 17 mars 2026 Xaira exec divulges R&D focus, how $1B fundraise fuels AI-driven hunt for what the 'industry is hungriest for'
FierceBiotech 17 mars 2026 FDA rejects Aldeyra dry eye disease drug for 3rd time, citing inconsistent study findings
FierceBiotech 17 mars 2026 Hitting regulatory roadblock, Bicycle pumps brakes on lead program and deflates headcount by 30%
FierceBiotech 17 mars 2026 BioVie plans $20M IPO for spinout tasked with developing liver disease drug
FierceBiotech 17 mars 2026 R1 zooms out of stealth with $77.5M series A to advance chronic kidney disease treatment
FierceBiotech 17 mars 2026 Roche inks Nvidia deal to bolster AI factory, speed up drug and diagnostic development